Such information would be critical for a future development of animal models with a tissue-specific suppression or potentiation of expression of the α2-AR isoforms, as well as for a prospective new gene- or cell-based therapies aimed at treating cardiomyopathy and heart failure [1]. This evidence concerns the gene ADORA2A and cardiomyopathy.